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Mid-trimester termination ofpregnancy - a randomised
controlled trial of two prostaglandin regitnens
D. W. STEYN, M. P. PIENAAR
Abstract Objective. To detennine the more applicable of
two ways of prostaglandin induction currently in
use in second triInester induced abortions for con-
genital or chromosomal abnormalities.
Design. A prospective randomised controlled
trial.
Setting. Department of Obstetrics and Gynae-
cology, Tygerberg Hospital, CP.
Study population. Twenty consecutive patients
admitted for tennination of pregnancy for con-
genital or chromosomal abnormalities between 14
and 26 weeks' pregnancy duration.
Management. Patients were randomly selected
to receive either 1,5 mg prostaglandin E, (PGE,)
gel extra-amniotically or 25 mg prostaglandin F,a
(PGF,a) intra-amniotically. Patients in both
groups received oxytocin to a maximum dosage of
120 IllU per minute if they had not aborted 18
hours after the original administration of either
prostaglandin regimen. If abortion had not taken
place 36 hours after cotnmencement of treatment,
management was considered unsuccessful.
Main outcome measurements. Proportion of
successful inductions and cOIllplications.
Results. Complications of management were
rare and did not differ between the two manage-
ment groups. However, there were significantly
more failures in the group who receh'ed intra-
amniotic PGF,a (7 v. 2 patients) as well as a signi-
ficantly higher need for oxytocin in this group
(10 v. 4 patients).
Conclusions. With· proIllising drugs such as
prostaglandin analogues and anti-progesterones
not universally available, methods of induction
suitable to the local situation should be sought.
Extra-atnniotic PGE, seems more suitable than
intra-amniotic PGF,a because of a shorter induc-
tion-to-delivery time without increased morbidity.
S AIr MedJ 1993; 83: 737-738.
Fe~al genetic disord~rs and congenital abnormali-tles are mostly dIagnosed during the secondtrimester when termination of pregnancy (TOP)
is often the parental choice. Mid-trimester TOP has
been complicated by serious maternal morbidiry! and
prolonged, often ineffective, procedures.' The use of
prostaglandins for mid-trimester TOP has been ade-
quately described,' although variations in methods
and dosages have precluded definite conclusions as to
the best method for second trimester TOP. We exam-
ined two methods of prostaglandin induction currently
used in our unit to determine which is more appropriate
in second-trimester induced abortions for congenital or
chromosomal abnormalities.
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Subjects and methods
A randomised controlled trial was performed to evaluate
the use of extra-amniotic prostaglandin E, (PGE,) gel
compared with intra-amniotic prostaglandin F,cx
(pGF,cx). Twenty successive patients admitted for TOP
at gestational ages between 14 and 26 weeks qualified
for the study. Exclusion criteria were a dead fetus on
admission, previous uterine scars, a history of asthma,
active vaginal or intra-uterine infection and anhydram-
nios. Patients were randomly allocated to one of two
management groups according to the balanced block
method. One group received 1,5 mg PGE, gel extra-
amniotically (prepidil gel; Upjohn). These patients were
examined in the lithotomy position. With the aid of a
Cuscoe speculum, the anterior lip of the cervix was
visualised and stabilised with a swab holder. Three
syringes each containing 0,5 mg PGE, gel were used in
immediate succession to instil the prostaglandin through
the cervix. The other group received intra-amniotic
PGF,cx_ Aspiration of 2 ml of amniotic fluid trans-
abdominally to confirm correct position of the needle
was followed by an injection of 5 mg PGF,cx. After 5
minutes, a bolus of 20 mg of the drug was administered
if no side-effects had occurred. The needle was then
removed. After 18 hours, 30 mU oxytocin per minute
were administered intravenously if the patient had not
yet aboned, irrespective of the original regimen. This
dosage was increased every 15 minutes, until a maxi-
mum of 120 mU per minute was reached. If the patient
had not aboned 36 hours after initiation of treatment,
the method was regarded as unsuccessful and the man-
aging physician was free to change over to management
of choice. Instructions for initial management were
placed in sealed envelopes and the procedures were per-
formed by the registrar rotating through the obstetric
special care unit. Informed consent was obtained from
patients and the study was approved by the Ethics
Committee of Tygerberg Hospital.
Results were analysed by means of Student's Hest to
compare means of normally distributed data and the
signed rank test for data not normally distributed. Ratios
were compared by means of Fisher's exact test because
of small numbers. P-values of less than 0,05 were con-
sidered significant.
Results
Patient characteristics were comparable in the two
groups (Table I). The difference in the number of
primigravidas was not statistically significant. The indi-
cations for termination are listed in Table n. Seventeen
terminations (85%) were performed either because of
genetic disorders or fetal abnormalities of the central
nervous system and these were evenly distributed
among the two groups. Complications of management
were extremely rare. There were no cases of uterine
hyperstimulation, excessive haemorrhage before or after
abortion or chorio-amnionitis in either group. The 1
case of nausea was managed successfully with anti-
emetic treatment. Other complications are derailed in
Table Ill. The 2 patients with retained placentas
required manual removal thereof under general anaes-
thesia. Rupture of membranes before abortion occurred
more often in patients who had received PGF,cx, but the
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TABLE/.
Comparison of patient characteristics in the two man-
agement groups
TABLE 11.
Indications for termination of pregnancy in the two man-
agement groups
average duration of rupture before delivery was shon
(3,44 hours). Oxytocin was needed in all patients receiv-
ing PGF,Ci, but only in 4 of the patients receiving PGE,
(P < 0,05). Induction-to-delivery time was on average
almost 14 hours longer in the intra-amniotic group and
significantly more failures occurred in this group (Table
ill). While more analgesics were used on average by the
intra-amniotic group, this difference was not statistically
significant and was at least partially the result of the
longer time that elapsed between induction and delivery
in this group.
PGF,C( group PGE, group P-value
Maternal age 27,11 (20 - 38) 30,22 (23 - 40)
Median 27 29,3 NS
Gravidity 2,22 (1 - 4) 2,89 (2 - 4)
Median 2 3 NS
Parity 0,78 (0 - 3) 1,56 (0 - 3)
Median 0 1 NS
Nulliparas 5 1 NS
Miscarriages 0,56 (0 - 3) 0
Median 0 0 NS
Gestational age 22,2 (18 - 26) 22,8 (19 - 26)
Median 22 22,3 NS
Bishop count
< 4 at onset 10 10 NS
Race group
White 4 4 NS
Coloured 5 5
NS = not significant.
Discussion
Procedures for eventual mid-trimester TOP should not
be complicated by an unduly long induction process.
Given a lack of prostaglandin analogues and anti-pro-
gesterones,4,5 at present prostaglandins seem the most
appropriate way of achieving this goal locally. The exis-
tence of many methods for TOP emphasises that no
panicular one is optimal. Furthermore, studies have
often been performed on patients at an earlier gesta-
tional age than those in our study. This study was
undenaken to determine which of two regimens is the
most suitable in local circumstances.
The major differences between the two routes of
administration was that patients in whom labour was
induced by means of extra-amniotic PGE, had a signifi-
cantly bener chance of delivering within 36 hours than
those induced by means of intra-amniotic PGF,Ci. They
also needed oxytocin augmentation less often and for
shoner periods of time. This conclusion might be preju-
diced by the higher number of nulliparas in the laner
group.' However, there was no difference in the initial
Bishop scores between the two groups. In addition, oxy-
tocin was needed in all patients receiving intra-amniotic
prostaglandin. Furthermore, in this particular group, the
difference in induction-to-delivery time was not signifi-
cantly longer in the nulliparas than in the multiparas.
Both regimens might be adjusted to improve results
further. It has been reponed that an increase to 2,5 mg
in the dosage of PGE, given extra-amniotically leads to a
shorter induction-ta-labour time compared with a
dosage of 1,5 mg, without an increase in morbidity.'
Likewise, some recommend that the dosage of intra-
amniotic PGF,Ci should be 40 - 50 mg if only a single
dose is administered.7 .
This small study, initially intended as a pilot study,
confirms that methods of induction suitable to local cir-
cumstances should be sought. Extra-amniotic PGE,
seems more appropriate than intra-amniotic PGF,Ci
because of a shorter induction-to-delivery time without
increased morbidity. The situation with regard to avail-
ability of alternative methods should, however, be
reviewed constantly and modifications of policy investi-
gated. Continuation of the present study is thus not
warranted.
We would like to thank the Medical Superintendent of
Tygerberg Hospital for permission to publish, and Upjohn
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1
2
o
1
1
5
PGE, group
3
3
1
o
o
3
PGF,C( group
Genetic disorders'
Central nervous system
Anencephaly
Hydrocephaly
Other
Conjoined twins
(cephalothoracophagus)
Cystic lung tumour
Multiple pterygium syndrome
*Excluding multifactorial causes.
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